Hannes Buchner

696 total citations
22 papers, 430 citations indexed

About

Hannes Buchner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Hannes Buchner has authored 22 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Hannes Buchner's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Hannes Buchner is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Hannes Buchner collaborates with scholars based in Germany, Austria and United States. Hannes Buchner's co-authors include Eva Rehfuess, Hans Dieplinger, P Stieber, Arno Lingenhel, Alexander Burges, Miriam Lenhard, Donna P. Ankerst, Wolfgang Otto, Hans‐Martin Fritsche and Stefan Denzinger and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Hannes Buchner

21 papers receiving 418 citations

Peers

Countries citing papers authored by Hannes Buchner

Since Specialization

Citations

This map shows the geographic impact of Hannes Buchner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hannes Buchner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hannes Buchner more than expected).

Fields of papers citing papers by Hannes Buchner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hannes Buchner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hannes Buchner. The network helps show where Hannes Buchner may publish in the future.

Co-authorship network of co-authors of Hannes Buchner

This figure shows the co-authorship network connecting the top 25 collaborators of Hannes Buchner. A scholar is included among the top collaborators of Hannes Buchner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hannes Buchner. Hannes Buchner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNIS 2024 ·Translational Lung Cancer Research ·Martin Reck, K. Syrigos, Skaidrius Miliauskas, (unknown), Bartomeu Massutí, Hannes Buchner, Alexey V. Salnikov, Robert M. Lorence, (unknown), Thomas Kitzing, Keith M. Kerr	0
2	Optimising cell-based bioassays via integrated design of experiments (ixDoE) - A practical guide 2022 ·SLAS DISCOVERY ·Johannes Solzin, (unknown), Bettina L. Knapp, Hannes Buchner, (unknown)	1
3	Optimising Cell-Based Bioassays Via Integrated Design of Experiments (ixDoE) - a Practical Guide 2022 ·SSRN Electronic Journal ·Johannes Solzin, (unknown), Bettina L. Knapp, Hannes Buchner, (unknown)	1
4	Estimands for overall survival in clinical trials with treatment switching in oncology 2021 ·Pharmaceutical Statistics ·Juliane Manitz, (unknown), Hannes Buchner, (unknown), Evgeny Degtyarev, Jyotirmoy Dey, Vincent Haddad, (unknown), Emily J. Martin, (unknown), Kaspar Rufibach, Yue Shentu, Viktoriya Stalbovskaya, Rui Tang, (unknown), (unknown)	16
5	Real-World Efficacy of Docetaxel Plus Nintedanib After Chemo-Immunotherapy Failure in Advanced Pulmonary Adenocarcinoma 2021 ·Future Oncology ·Martin Metzenmacher, (unknown), Kato Kambartel, Jens Panse, (unknown), Matthias Scheffler, (unknown), Mathias Hoiczyk, Amin T. Turki, Judith Atz, Hannes Buchner, Christopher M. Hoffmann, Daniel C. Christoph	7
6	Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy 2020 ·Lung Cancer ·Martin Reck, Kostas Syrigos, Skaidrius Miliauskas, Sabine Zöchbauer‐Müller, Jürgen R. Fischer, Hannes Buchner, Thomas Kitzing, R. Kaiser, (unknown), Keith M. Kerr	18
7	Action Limit Outlier Test: A Novel Approach for the Identification of Outliers in Bioassay Dose–Response Curves 2020 ·Bioanalysis ·Johannes Solzin, Hannes Buchner, Alexander Berger, (unknown), (unknown), Erich Bluhmki	2
8	Nintedanib (N) + docetaxel (D) after immunotherapy in adenocarcinoma non-small cell lung cancer (NSCLC): First results from the non-interventional LUME-BioNIS study 2019 ·Annals of Oncology ·Martin Reck, K. Syrigos, Skaidrius Miliauskas, Sabine Zöchbauer‐Müller, Hannes Buchner, Thomas Kitzing, Keith M. Kerr	2
9	Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study 2018 ·OncoTargets and Therapy ·Martin Reck, Anders Mellemgaard, Silvia Novello, Pieter E. Postmus, Birgit Gaschler‐Markefski, R. Kaiser, Hannes Buchner	13
10	Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306). 2018 ·Journal of Clinical Oncology ·Volker Heinemann, (unknown), Hannes Buchner, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Frank Kullmann, Markus Moehler, Werner Scheithauer, Swantje Held, Dominik Paul Modest, Jens Neumann, Andreas Jung, Thomas Kirchner, Sebastian Stintzing	13
11	Oral nutritional supplement for children with cancer: 7 different high-energy drinks compared to cacao, a double-blinded feeding trial 2018 ·Aktuelle Ernährungsmedizin ·(unknown), Hannes Buchner, Heather Bauer, Irene Schmid	1
12	Cooking and Season as Risk Factors for Acute Lower Respiratory Infections in African Children: A Cross-Sectional Multi-Country Analysis 2015 ·PLoS ONE ·Hannes Buchner, Eva Rehfuess	40
13	Tumor growth over time in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology (ACH) treated with nintedanib and docetaxel or placebo and docetaxel: Analysis of data from the LUME-Lung 1 (LL1) study. 2015 ·Journal of Clinical Oncology ·Martin Reck, Hannes Buchner, Maya Gottfried, Silvia Novello, Anders Mellemgaard, Birgit Gaschler‐Markefski, R. Kaiser, Jean‐Yves Douillard	1
14	The vitamin E-binding protein afamin increases in maternal serum during pregnancy 2014 ·Clinica Chimica Acta ·(unknown), Hannes Buchner, M Mörtl, Dietmar Schlembach, Berthold Huppertz, (unknown), Wolfgang Köhler, E. Hafner, Benjamin Dieplinger, L. Wildt, Hans Dieplinger	40
15	Effect of Nintedanib (Bibf 1120) Combined with Standard 2Nd-Line Docetaxel in Nsclc Patients Who Received Prior Pemetrexed in Lume-Lung 1: a Randomised, Placebo-Controlled Phase III Trial 2014 ·Annals of Oncology ·Anders Mellemgaard, Sergey Orlov, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, José Barrueco, Hannes Buchner, (unknown), R. Kaiser, Silvia Novello, Jean‐Yves Douillard, Martin Reck	3
16	The vitamin E–binding protein afamin is altered significantly in the peritoneal fluid of women with endometriosis 2010 ·Fertility and Sterility ·Beata Seeber, Theresa Czech, Hannes Buchner, Kurt T. Barnhart, Christoph Seger, Guenter Daxenbichler, L. Wildt, Hans Dieplinger	27
17	Multicolor FISH (UroVysion) Facilitates Follow-up of Patients With High-Grade Urothelial Carcinoma of the Bladder 2010 ·American Journal of Clinical Pathology ·Hans‐Martin Fritsche, Maximilian Burger, Wolfgang Dietmaier, Stefan Denzinger, (unknown), Wolfgang Otto, (unknown), Stephan Schwarz, Hannes Buchner, Arndt Hartmann	34
18	Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer 2010 ·Clinical Cancer Research ·Stefan Boeck, Michael Haas, Rüdiger P. Laubender, Frank Kullmann, Christina Klose, Christiane J. Bruns, Ralf Wilkowski, P Stieber, Stefan Holdenrieder, Hannes Buchner, Ulrich Mansmann, Volker Heinemann	35
19	Predicting individual outcomes after radical cystectomy: an external validation of current nomograms 2009 ·British Journal of Urology ·Dirk Zaak, Maximilian Burger, Wolfgang Otto, Patrick J. Bastian, Stefan Denzinger, Christian G. Stief, Hannes Buchner, Arndt Hartmann, Wolf F. Wieland, Shahrokh F. Shariat, Hans‐Martin Fritsche	60
20	[Familial congenital liver cirrhosis and renal deformity in cholesterol deposition disease]. 1957 ·PubMed ·H Berger, (unknown), Hannes Buchner, (unknown), Rebecka S. Hess, (unknown), K. Bernhard	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact